Walleye Partners’s ImmunityBio IBRX Stock Holding History

Walleye Partners’s Portfolio IBRX Stock Details IBRX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$105K	Buy	11,997 +603	+5%	+$4.56K	0.12%	59
2026 Q1	$87.4K	Buy	+11,394	New	+$78K	0.11%	54

Other funds holding IBRX

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return

Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Millennium Management New York $276B AUM 44.8% 1-Year Est. Return

Northern Trust Chicago, Illinois $860B AUM 41.15% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Walleye Partners's IBRX Position: Q2 2026 in Review

Walleye Partners increased its ImmunityBio (IBRX) stake by 5.3% in Q2 2026, buying an estimated $4.56K and bringing the position to 11,997 shares worth $105K. The position accounts for 0.12% of the portfolio, ranked #59.

Walleye Partners first reported a position in IBRX in Q1 2026 and has held it in 2 quarters since. 402 funds tracked by Wall St. Rank hold IBRX as of Q2 2026.

Walleye Partners held 11,997 shares of ImmunityBio worth $105K as of Q2 2026.
Walleye Partners bought 603 ImmunityBio shares in Q2 2026, an estimated $4.56K.
ImmunityBio made up 0.12% of Walleye Partners's portfolio in Q2 2026, its #59 holding.
Walleye Partners first reported a position in ImmunityBio in Q1 2026 and has held it in 2 quarters since.
402 funds tracked by Wall St. Rank held ImmunityBio as of Q2 2026.

Based on Walleye Partners's 13F filing for Q2 2026, filed 24 Jul 2026.